Overview

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of Levetiracetam augmentation relative to Placebo in SSRI non-remitters with obsessive compulsive disorder. The hypothesis is that anxiolytic effect of Levetiracetam is more beneficial when adding with a SSRI.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Duke University
Collaborator:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam
Sertraline